UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Novel treatment strategies in rheumatoid arthritis

The Lancet (British edition), 2017-06, Vol.389 (10086), p.2338-2348

2017

Volltextzugriff (PDF)

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus

Annals of the rheumatic diseases, 2015-07, Vol.74 (7), p.1474-1478

2015

Volltextzugriff (PDF)

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

Annals of the rheumatic diseases, 2015-06, Vol.74 (6), p.1037-1044

2015

Volltextzugriff (PDF)

The etiology of rheumatoid arthritis

Journal of autoimmunity, 2020-06, Vol.110, p.102400-102400, Article 102400

2020

Volltextzugriff (PDF)

Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus

Annals of the rheumatic diseases, 2016-07, Vol.75 (7), p.1407-1415

2016

Volltextzugriff (PDF)

Rheumatology 4.0: big data, wearables and diagnosis by computer

Annals of the rheumatic diseases, 2018-07, Vol.77 (7), p.963-965

Burmester, Gerd R

2018

Volltextzugriff (PDF)

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials

Arthritis care & research (2010), 2019-03, Vol.71 (3), p.367-378

2019

Volltextzugriff (PDF)

Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE

Annals of the rheumatic diseases, 2015-04, Vol.74 (4), p.791-792

2015

Volltextzugriff (PDF)

2016 update of the EULAR recommendations for the management of early arthritis

Annals of the rheumatic diseases, 2017-06, Vol.76 (6), p.948-959

2017

Volltextzugriff (PDF)

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab

Annals of the rheumatic diseases, 2015-02, Vol.74 (2), p.415-421

2015

Volltextzugriff (PDF)

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

The Lancet (British edition), 2017-06, Vol.389 (10086), p.2317-2327

2017

Volltextzugriff (PDF)

Selective depletion of plasma cells in vivo based on the specificity of their secreted antibodies

European journal of immunology, 2020-02, Vol.50 (2), p.284-291

2020

Volltextzugriff (PDF)

Therapeutische Antikörper in der Rheumatologie

Zeitschrift für Rheumatologie, 2024-03, Vol.83 (2), p.98-104

2024

Volltextzugriff (PDF)

The Diagnosis and Treatment of Sjögren's Syndrome

Deutsches Ärzteblatt international, 2017-05, Vol.114 (20), p.354-361

2017

Volltextzugriff (PDF)

Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register

Annals of the rheumatic diseases, 2022-01, Vol.81 (1), p.41-47

2022

Volltextzugriff (PDF)

Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases

Annals of the rheumatic diseases, 2022-06, Vol.81 (6), p.881-888

2022

Volltextzugriff (PDF)

Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease

Annals of the rheumatic diseases, 2022-09, Vol.81 (9), p.1313-1322

2022

Volltextzugriff (PDF)

EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2

Annals of the rheumatic diseases, 2020-07, Vol.79 (7), p.851-858

2020

Volltextzugriff (PDF)

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study

The Lancet (British edition), 2016-12, Vol.388 (10061), p.2763-2774

2016

Volltextzugriff (PDF)

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis

Annals of the rheumatic diseases, 2020-06, Vol.79 (6), p.760-770

2020

Volltextzugriff (PDF)

Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus

Annals of the rheumatic diseases, 2013-09, Vol.72 (9), p.1549-1558

2013

Volltextzugriff (PDF)

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

Annals of the rheumatic diseases, 2022-03, Vol.81 (3), p.335-343

2022

Volltextzugriff (PDF)

Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial

The Lancet (British edition), 2020-07, Vol.396 (10246), p.267-276

2020

Volltextzugriff (PDF)

Digital crowdsourcing: unleashing its power in rheumatology

Annals of the rheumatic diseases, 2020-09, Vol.79 (9), p.1139-1140

2020

Volltextzugriff (PDF)

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

Annals of the rheumatic diseases, 2013-04, Vol.72 (4), p.517-524

2013

Volltextzugriff (PDF)

1 – 25 von 864

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(748)
Mit Volltextzugriff
(684)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(601)
Life Sciences & Biomedicine
(593)
Humans
(492)
Rheumatology
(482)
Rheumatoid Arthritis
(243)
Female
(236)
Male
(222)
Middle Aged
(207)
Adult
(191)
Biological And Medical Sciences
(151)
Arthritis, Rheumatoid - Drug Therapy
(147)
Medical Sciences
(144)
Aged
(134)
Patients
(122)
Antirheumatic Agents - Therapeutic Use
(112)
Treatment Outcome
(111)
Diseases Of The Osteoarticular System
(89)
Arthritis
(84)
Immunology
(83)
Arthritis, Rheumatoid - Immunology
(67)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Novel treatment strategies in rheumatoid arthritis

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

The etiology of rheumatoid arthritis

Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus

Rheumatology 4.0: big data, wearables and diagnosis by computer

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials

Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE

2016 update of the EULAR recommendations for the management of early arthritis

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Selective depletion of plasma cells in vivo based on the specificity of their secreted antibodies

Therapeutische Antikörper in der Rheumatologie

The Diagnosis and Treatment of Sjögren's Syndrome

Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register

Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases

Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease

EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis

Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial

Digital crowdsourcing: unleashing its power in rheumatology

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

Suchergebnisse filtern